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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a fatal multifactorial neurodegenerative disease characterized
by selective death of motor neurons in the cortex, brainstem, and spinal cord. Cytosolic phospholipase A2 alpha
(cPLA2α) upregulation and activation in the spinal cord of patients with sporadic ALS and in the spinal cord of
human mutant SOD1G93A (hmSOD1) transgenic mice were recently reported.
Methods: cPLA2α upregulation in the brainstem and spinal cord was reduced by brain infusion of a specific
antisense oligonucleotide against cPLA2α (AS), and the effect was evaluated on disease progression and brain cell
activation.
Results: We found that the elevation of cPLA2α protein expression in the spinal cord was first detected at 6-week-old
hmSOD1 mice and remained elevated during their whole life span. Reduction of the elevated expression of cPLA2α in
the spinal cord of hmSOD1 mice by brain infusion of an AS at week 15 (shortly before the appearance of the disease
symptoms), for a duration of 6 weeks, delayed the loss of motor neuron function in comparison with hmSOD1 mice
and with sense brain-infused hmSOD1 mice. To characterize the effect of cPLA2α upregulation on different processes
taking place at the appearance of the disease symptoms, mice were brain infused with AS or with sense at week 15
for 3–4 weeks. The AS treatment that reduced cPLA2α upregulation in the spinal cord of AS-treated hmSOD1 mice
(as analyzed at week 18–19) prevented the reduction in the number of the neurons (detected by NeuN) and inhibited
astrocyte activation (detected by GFAP) and microglia activation (detected by Iba-1 and by CD40). In addition, AS
treatment blunted the upregulation of the proinflammatory enzyme-inducible nitric oxide synthase (iNOS) and
cyclooxygenase-2 (COX-2) detected in hmSOD1 mice.
Conclusions: Since specific reduction of cPLA2α in the brainstem and spinal cord significantly attenuated the
development of the disease, cPLA2α may offer an efficient target for treatment of ALS.
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Background
Amyotrophic lateral sclerosis (ALS) is a severe degenera-
tive disorder, mainly affecting the motor neurons in the
spinal cord, brainstem, and cortex. Most of the cases
(about 90 %) are sporadic. Familial cases have been
linked to mutations in a number of genes, including Cu/
Zn superoxide dismutase (SOD1), TAR DNA binding
protein (TDP-43), and chromosome 9 open reading
frame 72 (C9ORF72) repeat expansions [1]. Mutant
SOD1 is the best characterized form of familial ALS, ac-
counting for 15–20 % of familial cases [2]. The etiology
of sporadic ALS is unknown, although it is generally
believed that sporadic and familial ALS may share
pathological mechanisms. The pathophysiology of the
multifactorial-multisystemic ALS disease includes vari-
ous mechanisms. Among them are oxidative damage,
high levels of glutamate, a reduced secretion of neuro-
trophic factors, protein aggregations, malfunctioning of
the mitochondria, rupture in the axonal passage, de-
struction in the calcium metabolism, and changes in the
skeletal proteins [3]. Although ALS is not primarily con-
sidered an inflammatory or immune-mediated disease,
immune mechanisms appear to play a role in the patho-
genesis of the disease. In both ALS patients and animal
models, inflammatory responses have been observed
[3–5]. Microglia [6] and astrocytes [7] are activated
during the progression of the disease, and evidence
suggests that they contribute to neuronal death. Se-
lective ablation of mutant SOD1 in astrocytes and
microglial cells by conditional deletion [8] and neonatal
wild-type bone marrow transplantation [6] increased
motor neuron survival and life span. It has also been re-
ported that in the CNS, natural killer cells and peripheral
T cells infiltrate the spinal cord [9].
Previous findings suggested that cytosolic phospholipase
A2α (cPLA2α) is regarded as an important source of in-
flammation. cPLA2α specifically hydrolyzes phospholipids
containing arachidonic acid at the sn-2 position [10, 11]
and is generally thought to be the rate-limiting step in the
generation of eicosanoids and platelet-activating factor.
These lipid mediators play critical roles in the initiation
and modulation of inflammation and oxidative stress.
cPLA2α is ubiquitous in brain cells and is essential for
their physiological regulation. However, elevated cPLA2α
expression and activity were detected in the inflammatory
sites in a vast array of inflammatory diseases, including
neurodegenerative diseases [12–14]. Increased expression
and activity of cPLA2α have been detected in neurons, in
astrocytes, and in microglia in the spinal cord, brainstem,
and cortex of sporadic ALS patients [15] and in the spinal
cord of G93A human mutant transgenic (hmSOD1) mice
[16], suggesting that cPLA2α may have an important role
in the pathogenesis of the disease in all ALS patients. Due
to the complexity of biological pathways involved in ALS,
it is now thought that blunting several aspects of the dis-
ease may offer distinct advantages over targeting one
pathway. Since our previous studies showed that elevated
cPLA2α is involved in glia activation, oxidative stress [17]
and neuronal apoptotic death [18], targeting cPLA2α may
affect these processes that have been shown to be involved
in the pathogenesis of ALS. The present study aims to de-
termine whether the elevation of cPLA2α protein expres-
sion in the spinal cord and brainstem has a role in the




B6.Cg-Tg(SOD1G93A)1Gur/J hemizygous transgenic male
mice were obtained from Jackson Laboratory (Bar Harbor,
ME, USA). The hemizygous transgenic male mice were
also obtained by mating hemizygous transgenic males with
C57BL/6J females (Jackson Laboratory) so that each litter
would generate hemizygous SOD1G93A transgenic mice
and littermate wild-type controls. Transgenic male off-
springs were genotyped by PCR assay of DNA obtained
from tail tissue (according to Jackson Laboratory). The
study included male mice to avoid estrogen effect. The in-
fusion of anti-cPLA2α antisense oligonucleotide or corre-
sponding sense to mice (were performed as described in
our previous study [19] and according others [20–22]). A
microosmotic pump (Alzet, Durect Corp. Cupertino,
CA, USA) that had been filled with oligonucleotide
and incubated overnight in saline at 37 °C was im-
planted in a subcutaneous pocket. The pump that
was attached to a cannula (Alzet brain infusion kit 3,
Durect Corp. Cupertino, CA, USA) stereotaxically im-
planted into the right lateral cerebral ventricle
(−1.0 mm mediolateral and −0.5 mm anteroposterior
from Bregma). The study was approved by Ben-
Gurion University Institutional Animal Care and Use
Committee (IL-37-05-2012) and was conducted ac-
cording to the Israeli Animal Welfare Act following
the guidelines of the Guide for Care and Use of
Laboratory Animal (National Research Council, 1996).
Antisense oligonucleotide against cPLA2α
Antisense oligonucleotides against cPLA2α were engi-
neered using the computer-based approach RNADraw
V1.1 (Mazura Multimedia, Stockholm, Sweden). An
oligo-deoxynucleotide antisense (tcaaaggtctcattccaca)
and its corresponding sense with phosphorothioate
modifications on the last 3 bases at both 5′ and 3′
ends were used as described in our previous article
[19]. The specificity to cPLA2α was analyzed by blast
search program and was demonstrated in our previ-
ous study [23]. Mice (around 25 g of weight) received
10 μg/day phospho oligo-deoxynucleotides diluted in
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saline. The antisense concentration used in the study
reduced cPLA2α levels in the brainstem and spinal cord of
ALS mice to the level detected in wild-type mice.
Brain stem and spinal cord tissue preparation
Mice were deeply anesthetized and transcardially per-
fused with 20 ml of PBS [24].
For immunoblot analysis
Spinal cords were harvested in lysis buffer containing
50 mM Tris pH = 8, 150 mM NaCl, 1 % NP-40, 0.5 %
DOC, 0.1 % SDS, 10 μg/ml leupeptin, 1 mM phenyl-
methylsulfonyl fluoride, 10 μg/ml aprotinin, 1 mM ben-
zamidine, 20 mM P-nitrophenyl phosphate, 5 mM
Na3VO4,10 mM NaF, and 50 mM β-glycerol phosphate.
Soluble extracts were prepared by centrifugation at
13,000 g for 20 min at 4 °C. Lysate protein was separated
on SDS-PAGE electrophoresis and transferred to nitro-
cellulose membranes. Membranes were incubated in
Tris-buffered saline (10 mM Tris, 135 mM NaCl,
pH 7.4), with 0.1 % Tween 20 (TBS-T) containing 5 %
non-fat milk for 1.5 h at 25 °C. The blots were then in-
cubated with primary antibodies: 1:1000 rabbit poly-
clonal anti-cPLA2α against the carboxyterminal residues
(Cell Signaling Technology, Beverly, MA, USA), 1:1000
rabbit anti-COX-2 (Abcam, Cambridge, UK), 1:1000
rabbit anti-iNOS (Cayman chemical, Ann Arbor, MI,
USA), 1:500 rabbit anti-calreticulin (Thermo Scientific,
Rockford, IL, USA) as primary antibodies for overnight
at 4 °C. After washing with TBS-T, they were incubated
with secondary antibody peroxidase-conjugated goat
anti-rabbit (Amersham Biosciences, Buckinghamshire,
UK) for 1 h at 25 °C and developed using the enhanced
chemiluminescence (ECL) detection system (PerkinElmer,
Waltham, MA, USA). Proteins were quantified using
video densitometry analysis (ImageJ version 4.0 Fuji).
For immunostaining
The brainstem or spinal cord were fixed [25] in parafor-
maldehyde 4 %/PBS solution overnight at 4 °C. The
brainstem or spinal cord were then transferred to PBS
containing 30 % sucrose for 24 h and then embedded in
a 1:2 mixture of 30 % sucrose in PBS/Tissue-Tek OCT
(VWR, Radnor, PA, USA), frozen in liquid nitrogen and
stored at −80 °C. Sections were made by cryostat (Leica
Biosystems, Vienna, Austria) at 12-μm thickness, washed
in PBS/Tween 0.05 %, incubated in PBS/glycine 0.1 %
for 5 min, and incubated in a blocking solution (3 % nor-
mal donkey serum and 2 % BSA) at room temperature
for 1 h. Then, these sections were incubated with pri-
mary antibodies diluted in blocking solution overnight at
4 °C. The primary antibodies used in the study were
1:100 rabbit anti-cPLA2 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), 1:100 rabbit anti-pcPLA2α (Cell
Signaling Danvers, MA USA), 1:1000 rabbit anti-Iba-1
(Wako Chemicals Richmond, VA, USA), 1:500 rabbit
anti-GFAP (Dako Glostrup Denmark), 1:100 mouse anti-
NeuN (Millipore Darmstadt, Germany), and 1:100 rat
anti-CD40 or 1:100 rat anti-CD169 (AbD Serotec,
Kidlington, UK). Sections were washed with PBS/Tween
0.05 % and incubated with 1:200 Cy3 or 1:100 anti-
mouse Alexa488 or anti-rabbit DyLight-conjugated
secondary antibodies (Jackson Immunoresearch Labora-
tories, West Grove, PA, USA) for 1 h at room temperature.
For double staining, DyLight was used as a secondary anti-
body for cPLA2α (green) and 1:25 goat anti-Iba-1 (Novus
Biologicals Littleton, USA) or 1:100 mouse anti-GFAP
(Millipore Darmstadt, Germany) with Cy3 were used as
second antibodies (red). The staining of samples from the
different treatments was performed in parallel. For each
treatment, a negative control was prepared by omitting the
primary antibody. Sections were mounted with anti-fading
mounting medium (Electron Microscopy Sciences (EMS),
Hatfield, PA, USA) and photographed in a blinded
fashion using a fluorescent microscope (Olympus,
BX60, Hamburg, Germany) or with confocal micros-
copy (Olympus, FluoView 1000, Tokyo, Japan). Using
a confocal microscope, Z-sections were taken at 0.5-
μm intervals and the results present Z-stack images.
Fluorescence intensity was determined for cPLA2α
using CellProfiler program. The percentage of fluores-
cence intensity of the cell area was determined for
the different cell types using CellProfiler program.
Motor function measurement by rotarod
A rotarod test was used to evaluate the motor perform-
ance of the mice using an accelerating paradigm of
0.12 rpm/s. After a learning period of several days, mice
were able to stay on the rotarod (Rotamex-5, Columbus
instruments, Columbus, OH, USA) for up to 150 s. Each
mouse was given 3 trials and the best performance was
used as a measure for motor neuron ability. Mice were
tested twice a week from age of 7 weeks until they could
no longer perform the task.
Neurological score evaluation by ladder testing
To evaluate the animal’s overall neurological state, we
performed a neurological scoring based on the ladder
test described in details by others [26], which is an ex-
tension of the hanger test. Shortly, the ladder was placed
at a 45° angle; after a brief training period, healthy mice
quickly and efficiently climb up the ladder. As the dis-
ease progresses, the animals’ ability to climb was hin-
dered beginning with leg tremors and developing up
until the point where the mice can simply not climb up
the ladder at all. Mice were evaluated for their neuro-
logical score three times a week by a blinded observer.
The mice were scored based on their performance on
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the ladder test with a score of 12 representing com-
pletely healthy mice and 0 correlating with disease end
stage, described in details [26].
End-stage analysis
To determine the mortality in a reliable and human
fashion, end stage was defined as the inability of the
mice to right themselves 30 s after being placed on one
of their sides.
Statistical analysis
Data were expressed as mean ± standard error of the
mean (SEM). Significance was determined by either one-
or two-way analysis of variance (ANOVA) followed by a
posteriori Bonferroni’s test for multiple comparisons
provided by GraphPad Prism version 5.00 for Windows
(GraphPad Software, San Diego, CA, USA). Survival was
evaluated by Kaplan-Meier analysis.
Results
In order to study the role of cPLA2α in the development
of ALS, cPLA2α protein expression was analyzed in the
spinal cord of hmSOD1 mice (Fig. 1a) at different stages
during their life span (Fig. 1b). Immunofluorescence
staining and quantitation showed a significant (p < 0.001)
elevation of cPLA2α protein expression in the spinal cord
(Fig. 1a) of 6-week-old hmSOD1 mice, before the loss of
motor neuronal function that appeared around week 17
(Fig. 1c). cPLA2α upregulation was also detected in the
mice brainstem from week 6 onward and showed similar
results (not shown). Neuronal or glial cells were stained
by specific markers in the spinal cord of hmSOD1 mice at
the same time points (Fig. 1d). Immunofluorescence stain-
ing and quantitation of neurons in the spinal cord using
anti-NeuN showed a significant (p < 0.001) reduction in
the neuron cell area from week 19 that was further re-
duced at the end stage. The neurons were counted accord-
ing to their size and we found a similar reduction of
around 40 % at 19 weeks and around 60 % at end stage in
each group, suggesting that the reduction in cell area is
due to both the number and the size of the neurons. A
significant (p < 0.001) appearance of activated microglia
(M1 phenotype) could be detected in the spinal cord of
15-week-old hmSOD1 mice by Iba-1 or CD40 staining
that was gradually increased with age. The activation of
microglia at week 15 preceded neuronal damage (Fig. 1d)
and the appearance of motor neuron dysfunction (Fig. 1c).
Activated astrocytes determined by GFAP were signifi-
cantly (p < 0.001) detected in the spinal cord of 19-week-
old mSOD1 mice and were dramatically increased at the
end stage. Double staining with Iba-1 and anti-CD169
for the detection of monocytes revealed a significant
(p < 0.001) appearance of monocytes in the spinal
cord only at the end stage (Fig. 1e). As shown by
confocal microscopy in Fig. 2a and in the inset Fig. 2b,
double staining analysis of cPLA2α and the different
cell types suggests that the main cells expressing
cPLA2α protein are the neurons. High levels of
cPLA2α protein were detected in the large neurons
present in the spinal cord of mSOD1 mice at 6 and
11 weeks and in the small and damaged neurons at
19 weeks and end stage. The slight reduction of
cPLA2α protein expression at the end stage (Fig. 1a)
is probably due to the reduced number and size of
the neurons (Fig. 1d) which are the main cells ex-
pressing high levels of cPLA2α. Confocal microscopy
of higher magnification of the double staining analysis
of cPLA2α and Iba-1 or GFAP showed that elevated
cPLA2α could be detected in activated microglia and
astrocytes (Fig. 2b). Confocal microscopy of double
staining of the activated form of cPLA2α, phospho-
cPLA2α on serine 505 (pcPLA2α), and the markers of
the different cell types (Fig. 2c) showed that pcPLA2α
was detected in the nuclei of the cells.
To determine whether cPLA2α has a role in the induc-
tion of the disease, its expression was blunted in the
brain and spinal cord by means of specific oligonucleo-
tide antisense against cPLA2α at 6-week-old hmSOD1
mice, when the elevation of cPLA2α was first detected.
Ten micrograms per day of AS or the corresponding
sense or saline was continuously pumped into the right
lateral ventricle as done in our earlier study in a mouse
model of amyloid beta brain infusion [19]. Using this
methodology, it was shown [27] that significant oligo-
nucleotide concentrations were achieved in the brain
and brainstem and in all levels of the spinal cord. AS
brain infusion to 6-week-old mice over a period of
6 weeks significantly prevented upregulation of cPLA2α
in the brainstem as detected by immunofluorescence
(Fig. 3a) and in the spinal cord as detected by Western
blot analysis (Fig. 3b). As expected, at 12 weeks, there
was no neuronal damage as well as no activation of
microglia or astrocytes and the AS brain infusion had no
effect (Fig. 3a). This treatment that did prevent the
initial elevation of cPLA2α had no effect on the develop-
ment of the disease assayed by motor function on
rotarod (Fig. 3c). The initial value of 80 % of pre-
symptomatic is due to the pump implantation surgery.
To determine the role of cPLA2α in the progression of
the disease, 10 μg/day AS or sense was brain infused at
week 15 (shortly before the onset of motor neuronal
dysfunction) for 6 weeks (due to the pump’s limit). As
shown in Fig. 4a, AS brain infusion prolonged the sur-
vival in mice by 12 days (<0.05). AS brain infusion
significantly delayed the onset of motor neuron dysfunc-
tion by 3 weeks and there was a significant (p < 0.001)
difference between the two groups until 21 weeks of age
(Fig. 4b). Immediately after the pump implantation,
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there was a reduction in motor function, which was re-
covered only in the AS-treated hmSOD1 mice. The
evaluation of the overall motor symptoms change in
mice done by Ladder test (Fig. 4c) showed also a delay
of 3 weeks in the loss of motor neuron function in the
AS-treated hmSOD1 mice and a significant (p < 0.001)
difference from the sense-treated hmSOD1 mice until
23 weeks of age.
Fig. 1 cPLA2α protein levels in the spinal cord of hmSOD1 mice during the development of the disease in hmSOD1 mice. a Representative cPLA2α
protein expression in the spinal cord tissue sections along the hmSOD1 mouse life span. Scale bars = 250 μm for upper section and 50 μm for lower
sections. The mean ± SEM of the cPLA2α fluorescence intensity is presented in the bar graph (n= 8 mice for each time point, five fields were analyzed for
each mouse). *p< 0.001—significance from WT mice. b, c Development of the disease monitored by Kaplan-Meier survival curve and motor performance
on accelerating rotarod test (n= 12 mice in each group). d Representative spinal cord sections of neurons (NeuN), microglia (Iba-1 and CD40), and
astrocytes (GFAP) during the hmSOD1 mouse life span. The mean ± SEM of percentage of the cell area is presented in the bar graphs (n= 8 for each time
point, five fields were analyzed for each mouse). Scale bars = 50 μm and in the inset 20 μm. *p< 0.001—significance from WT mice. e Representative
staining of peripheral monocytes detected by double staining of Iba-1 and CD169, shown by arrows. Scale bars = 250 μm for left section and 50 μm for
right section in each pair. Scale bars in the insets = 20 μm. The mean ± SEM of number of monocytes and of percentage of the cell area is presented in
the bar graphs (n= 8 for each time point, five fields were analyzed for each mouse). *p < 0.001—significance in comparison to week 19
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Fig. 2 (See legend on next page.)
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To determine the processes that are affected by
cPLA2α during the development of the disease symp-
toms and to characterize the effect of prevention of
cPLA2α upregulation on the different processes taking
place at the first phase of development of motor neuron
dysfunction, hmSOD1 mice were brain infused with AS
or sense at week 15 for 3–4 weeks and the experiments
were terminated for analysis at 18–19 weeks of age, at a
time when the two mouse groups—AS and sense con-
trol—exhibited a significant difference in the disease
symptoms. Non-treated hmSOD1 mice and WT mice at
the same age were also studied. As shown in the im-
munofluorescence analysis and quantitation in Fig. 5a,
cPLA2α protein expression was much lower in the spinal
cord of 18–19-week-old AS-treated hmSOD1 mice in
comparison with hmSOD1 mice or sense-treated
hmSOD1 mice. AS treatment prevented the reduction in
the number of the neurons (detected by NeuN), pre-
vented astrocyte activation (detected by GFAP), and
inhibited microglia activation (detected by Iba-1 and by
CD40) compared with hmSOD1 mice or sense-treated
hmSOD1 mice. In AS-treated hmSOD1 mice, reduction
of cPLA2α upregulation led to diminution of the key in-
flammatory enzymes; iNOS and COX-2 as detected by
Western blot analysis in the spinal cord lysates (Fig. 5b).
Discussion
We show herein that cPLA2α is upregulated in the
spinal cord of 6-week-old mice long before the appear-
ance of the disease symptoms, neuronal death, or gliosis
and remained elevated during the whole life span of the
hmSOD1 mice. Prevention of cPLA2α upregulation at
the pre-symptomatic period (between 6 and 12 weeks)
did not affect the course of the disease. However, pre-
vention of cPLA2α upregulation shortly before the onset
of the disease symptoms significantly (p < 0.001) delayed
the loss of motor neuronal function, suggesting that
cPLA2α upregulation in the spinal cord plays a role in
the disease pathology. In line with our results, the role
of elevated spinal cord cPLA2α in neuronal damage was
reported also in spinal cord injury [28] and in spinal in-
flammatory hyperalgesia [29].
In the present study we used, specific antisense
brain infusion in order to determine the specific role
of cPLA2α upregulation in the spinal cord in the
pathogenesis of ALS. The advantage of the AS tech-
nique over knockout mice is its ability to inhibit the
induction of an accelerated protein at the site of in-
flammation, and enables its expression at basal levels,
whereas in knockout mouse models total elimination
of a protein may result in dramatic changes of
homeostasis and/or compensation by upregulation of
other proteins (with similar biological features). The
use of AS strategy is reinforced by two recent studies
in cPLA2α knockout mice reporting that total elimin-
ation of cPLA2α resulted with abnormalities in archi-
tecture of synapses and cortical neurons [30] as well
as in alteration of brain phospholipid composition
[31]. AS brain infusion to 15-week-old hmSOD1 mice
(for 6 weeks) shortly before the development of
motor dysfunction resulted in reduction of cPLA2α
elevated protein expression (as detected at 18–
19 weeks in the spinal cord) and significantly delayed
the development of the disease symptoms. This blunt-
ing of cPLA2α upregulation resulted in inhibition of
activation of microglia and astrocytes as well as inhib-
ition of motor neuronal death, as detected by im-
munofluorescence analysis in the spinal cord of 18–
19-week-old hmSOD1 mice.
A generation of mice expressing a conditional dele-
tion of the mutant SOD1 gene showed that each indi-
vidual cell types in the spinal cord contributes to the
development of ALS [8, 32]. Likewise, replacing the
myeloid lineage of mutant SOD1 mice with wild-type
microglia slowed disease progression [6]. Since
cPLA2α upregulation was detected in each cell type
in the spinal cord, it probably contributes by different
mechanisms to motor neuron dysfunction and cell
death: (i) elevated neuronal cPLA2α can act directly
in inducing neuronal death (ii) while elevated glial
cPLA2α can act indirectly by activating microglia and/
or astrocytes. In our recent study in primary neuronal
cultures, we reported that cPLA2α activation and up-
regulation induced apoptotic neuronal death [18].
Concomitant with our results, cDNA microarray ana-
lysis to monitor gene expression in the spinal cord of
hmSOD1 mice during neurodegeneration revealed
changes in apoptosis-related gene expression [4]. In
addition, the role of cPLA2α in glutamate excitotoxi-
city and oxidative stress-induced cell death in primary
(See figure on previous page.)
Fig. 2 Elevated cPLA2α protein expression in the different cell types of the spinal cord. a Representative pictures of immunofluorescence double
staining of cPLA2α (green) with motor neurons (NeuN), microglia (Iba-1), or astrocytes (GFAP) in the spinal cord during hmSOD1 mouse life span (out of
8 mice in each time point, presented in Fig. 1a). DAPI staining for cell nuclei. Scale bars = 20 μm. b Insets of the immunofluorescence double staining of
cPLA2α with motor neurons, microglia, or astrocytes (presented in a), in a higher magnification. Scale bars = 20 μm. c Immunofluorescence double
staining of phospho-cPLA2α (p-cPLA2) and motor neurons (NeuN), microglia (Iba-1) and astrocytes (GFAP). Shown representative immunofluorescence
confocal microscopy pictures (out of 8 mice in each group). Lower panel presents the cell staining and DAPI to show the cell nuclei. Scale bars = 20 μm
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spinal cord neuron cultures was recently reported
[33]. Taken together the studies in neuronal cultures
and the abundant levels of cPLA2α in motor neurons
in the spinal cord, it is suggested that neuronal
cPLA2α plays a direct role in motor neuron cell
death. Similar to other neurodegenerative diseases
and acute CNS insults, one of the most striking hall-
marks of ALS shared by familial and sporadic
patients, as well as by rodent models, is neuro-
inflammation, characterized by extensive microglial
activation and astrogliosis that contribute to disease
progression, rather than to its resolution [2, 34–36].
Fig. 3 Reduction of cPLA2α upregulation at the early stage did not affect the development of the disease. Mice were brain infused with 10 μg/day AS
(n = 12) or the corresponding sense (n = 6) or saline (n = 6) for 6 weeks starting at 6-week-old hmSOD1 mice. a Representative immunofluorescence
staining of cPLA2α, neurons (NeuN), microglia (Iba-1), and astrocytes (GFAP) in the brain stem tissue section of WT mice, hmSOD1 mice (ALS), hmSOD1
mice brain infused with AS (ALS + AS) or sense (ALS + SE) at 12 weeks. Mice receiving saline or sense showed similar results and were combined under
the sense-treated group. A double staining of cPLA2α and NeuN is presented. Scale bars = 50 μm, and in the insets = 20 μm. Shown are representative
images of 12 mice in each group. The mean ± SEM of the fluorescence intensity (for cPLA2α) and percentage of the cell area (for cell markers) are
presented in the bar graph. *p < 0.001—significance from WT mice and from AS-treated hmSOD1 mice. b A representative immunoblot analysis of
cPLA2α and the corresponding calreticulin protein expression in the spinal cord lysates of the mice. cPLA2α protein expression was determined by
dividing the intensity of each cPLA2α by the intensity of the corresponding calreticulin band after quantitation by densitometry and expressed in the
bar graph as arbitrary units. The bar graph is the mean ± SE of 8 mice in each group. *p < 0.001—significance from WT mice and from AS-treated
hmSOD1 mice. c Motor function by rotarod test of AS or sense brain infused-hmSOD1 mice (n = 12 in each group)
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Reduction of cPLA2α upregulation in the spinal cord
of the hmSOD1 mice prevented astrocyte activation
detected by GFAP immunostaining that is in line with
in vitro studies [37] reporting that activation of
cPLA2α led to an increase in oxidative stress in
astrocytes. We show here a massive activation of
microglia in the spinal cord (detected by immunostaining
of Iba-1 and CD40) that preceded the changes in the motor
neurons, in accordance with other studies [6, 38, 39]. This
microglia activation was shown to be cPLA2α dependent
coincided with ours and others’ studies in cell cultures
demonstrating the specific role of microglial cPLA2α in
the activation and transformation of microglia to M1
phenotype. We have previously reported that cPLA2α
activity regulated the production of superoxides by
NOX-2 NADPH oxidase and the induction of COX-2
and iNOS via nuclear factor kB (NF-kB) in microglia
cultures [17]. Interestingly, microglial NF-kB specific-
ally has been shown to play a major role in the develop-
ment of the ALS in hmSOD1 mice [40]. We show here
that reduction of cPLA2α in the spinal cord also de-
creased iNOS and COX-2 upregulation that produce
two major proinflammatory mediators; nitric oxide and
PGE2, respectively. As shown in the present study
for cPLA2α, it was also reported that in both early
symptomatic and end-stage transgenic hmSOD1 mice,
neurons and to a lesser extent glial cells in the spinal
cord exhibit robust COX-2 [41] and iNOS immunore-
activity [42]. Likewise, similar to cPLA2α, COX-2 was
dramatically increased in postmortem spinal cord sam-
ples from sporadic ALS patients [ 41]. Nitric oxide and
superoxides both under cPLA2α regulation [17] can
form the toxic reagent peroxynitrite [43, 44]. In this
context, a recent study reported that inhibition of
cPLA2α activity ameliorated experimental autoimmune
encephalomyelitis via blocking peroxynitrite formation
in mouse spinal cord white matter [45]. These results
suggest that glial cPLA2α is involved by different in-
flammatory processes in the development of ALS. In
accordance with this suggestion, injections of PLA2 into
the spinal cord of mice caused inflammation and oxida-
tive stress [46].
The cause of cPLA2α elevation in the brain and spinal
cord as early as 6-week-old mice is not yet clear. SOD1 in-
soluble protein complexes (IPCs) were detected in motor
neurons of 30-day-old mSOD1 mice [47], before the
manifestation of ALS pathology, and several months be-
fore the appearance of inclusion bodies. It may be possible
that the formations of IPCs in the neurons triggered the
elevation of cPLA2α. The role of this early elevation of
cPLA2α is also not known and prevention of this elevation
for 6 weeks had no effect on the course of the disease.
The role of monocyte recruitment to the spinal
cord in ALS is under debate. On one hand, it was re-
ported that inhibition of monocyte recruitment to the
spinal cord delayed motor dysfunction and increased
the survival of ALS mice [48]. In contrast, another
study [49] reported that monocytes could not be de-
tected in the spinal cord of SOD1G93A mice and that
Fig. 4 AS brain infusion to hmSOD1 mice shortly before the onset of
motor neuron dysfunction delayed development of the disease.
Fifteen-week-old hmSOD1 mice were brain infused with 10 μg/day AS
or the corresponding sense during 6 weeks (n = 12 in each group). AS
brain infusion prolonged survival (a), delayed loss of motor function
analyzed by Rotarod (b), and delayed neurological score analyzed by a
ladder (c). *p < 0.001—significance from sense-treated hmSOD1 mice
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microglia are not derived from infiltrating monocytes.
Likewise, a recent study [50] reported that in the
mutant SOD1G93A mouse model of ALS, the choroid
plexus of the brain did not support leukocyte traffick-
ing during disease progression, due to a local reduc-
tion in IFN-γ levels. The results of the present study,
Fig. 5 Reduction of cPLA2α upregulation in the spinal cord of hmSOD1 mice shortly before the onset of motor dysfunction reduced neuronal death
and gliosis. Fifteen-week-old hmSOD1 mice were brain infused with 10 μg/day AS or the corresponding sense for 3–4 weeks and analyzed at week 18–
19. a Representative immunofluorescence staining of cPLA2α, neurons (NeuN), microglia (Iba-1), and astrocytes (GFAP) in the spinal cord tissue section
of WT mice, hmSOD1 mice (ALS), hmSOD1 mice brain infused with AS (ALS + AS) or sense (ALS + SE) at 18–19 weeks. Scale bars = 50 μm. Shown are
representative images of 12 mice in each group. The mean ± SEM of the fluorescence intensity (for cPLA2α) and percentage of the cell area (for cell
markers) are presented in the bar graph. *p < 0.001—significance from WT mice and from AS-treated hmSOD1 mice. b Representative immunoblot
analysis of cPLA2α, COX-2, and iNOS and the corresponding calreticulin protein expression in the spinal cord lysates of the mice. Densitometry analysis
for the three proteins was done as described for cPLA2α in Fig. 3b. The bar graph is the mean ± SE of 8 mice in each group. *p < 0.001—significance
from WT mice and from AS-treated hmSOD1 mice
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in agreement with the two later reports, show that
the recruitment of monocytes detected by co-
immunostaining with CD169 and Iba-1 was evident
only at the end stage.
Conclusions
We show here that cPLA2α is elevated at 6 weeks,
long before the appearance of the disease symptoms.
cPLA2α elevation at the onset of symptoms plays a
role in the induction of motor dysfunction. Reduction
of cPLA2α upregulation shortly before the loss of
motor neurons function significantly delayed the ap-
pearance of the disease symptoms. Elevated neuronal
and glial cPLA2α may contribute by different aspects
involved in the pathogenesis of ALS. Thus, cPLA2α may
offer an efficient target for treatment of ALS and poten-
tially other multifactorial neurodegenerative diseases.
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